DocGo Projects 12%-20% Revenue Growth for 2026

Reuters
Nov 11
DocGo Projects 12%-20% Revenue Growth for 2026

DocGo Inc. has issued its 2026 financial guidance, projecting a base business revenue increase of 12% to 20%. This forecast is based on already contracted revenues and does not include potential new acquisitions or contract wins. The company expects that, at the top end of this revenue range, it will exit 2026 with a positive adjusted EBITDA run rate. For the third quarter of 2025, DocGo reported total revenue of $70.8 million, a decrease from $138.7 million in the same period of 2024, primarily due to the wind-down of migrant-related programs. Excluding these programs, revenue increased by 8% to $62.4 million compared to $58.0 million in the third quarter of 2024. The company also noted that, with the exception of care gap closure and primary care offerings, all service lines are adjusted EBITDA positive on a contribution basis. Investment in care gap and primary care is expected to decline significantly in 2026 as early markets mature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DocGo Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110397776) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10